AbbVie Inc.'s Stock Analysis

AbbVie Adjusts Earnings Guidance Due to Milestones Expense

AbbVie reported that its second quarter 2026 financial results will include an acquired IPR&D and milestones expense of $291 million, negatively impacting both GAAP and adjusted non-GAAP diluted earnings per share by $0.17. The company has provided a full-year adjusted diluted earnings per share guidance range of $13.91 to $14.11, which incorporates this expense, along with a second-quarter guidance range of $3.57 to $3.61.

The company indicated that it does not forecast future acquired IPR&D and milestones expenses due to the uncertainty surrounding the timing and occurrence of related transactions. This guidance excludes any additional expenses that may arise beyond the second quarter of 2026, highlighting the unpredictable nature of such costs in AbbVie's financial outlook.

Jul 06, 2026 16:12:09

AbbVie to Acquire Apogee for $10.9 Billion in Cash

AbbVie has announced a definitive agreement to acquire Apogee Therapeutics for $135.11 per share in cash, totaling approximately $10.9 billion. This acquisition aims to enhance AbbVie's immunology portfolio by incorporating Apogee's clinical-stage candidates targeting inflammatory and immunological diseases, including atopic dermatitis and asthma. The transaction has been unanimously approved by both companies' boards and is expected to close in the third quarter of 2026, pending regulatory approvals and shareholder consent from Apogee.

The acquisition is projected to be accretive to AbbVie's adjusted diluted earnings per share starting in 2032. Apogee's lead asset, zumilokibart, has shown promising results in clinical trials for atopic dermatitis, demonstrating significant skin clearance and itch reduction. AbbVie aims to leverage its scientific expertise to advance Apogee's pipeline, which includes innovative therapies that could address significant unmet medical needs in the immunology sector.

Jun 22, 2026 07:11:21

AbbVie Announces Results from 2026 Annual Stockholders Meeting

AbbVie conducted its 2026 Annual Meeting of Stockholders on May 8, 2026. The meeting included a summary of the matters that were voted on by the stockholders, although specific details regarding the votes or outcomes were not provided.

May 12, 2026 17:01:51

AbbVie Annual Meeting of Stockholders Held on May 8, 2026

AbbVie conducted its 2026 Annual Meeting of Stockholders on May 8, 2026. The meeting covered various matters that were voted on by the stockholders, although specific details of the votes were not provided in the summary.

May 12, 2026 17:01:51

AbbVie Reports Q1 2026 Financial Results and Guidance Update

AbbVie reported first-quarter 2026 net revenues of $15.002 billion, reflecting a 12.4% increase on a reported basis and a 10.3% increase operationally. The immunology portfolio generated $7.290 billion in revenues, marking a 16.4% increase, driven by strong performances from Skyrizi and Rinvoq. The neuroscience portfolio also saw significant growth with $2.875 billion in revenues, up 26.0%. However, the oncology portfolio experienced a slight decline of 0.2%, while the aesthetics portfolio increased by 7.6%. The diluted earnings per share (EPS) was $0.39 on a GAAP basis, with adjusted diluted EPS at $2.65, which includes a negative impact of $0.41 per share from acquired IPR&D and milestones expenses.

AbbVie has raised its adjusted diluted EPS guidance for the full year 2026 from a range of $13.96 - $14.16 to $14.08 - $14.28, also accounting for the unfavorable impact of acquired IPR&D and milestones expenses. The company is advancing multiple programs in its pipeline, including submissions for FDA approvals for Skyrizi and Rinvoq in new indications. AbbVie also announced substantial investments in manufacturing facilities aimed at enhancing production capabilities for its immunology, neuroscience, and oncology products.

Apr 29, 2026 07:50:28

AbbVie Reports Earnings Impact from Acquired IPR&D Expenses

AbbVie anticipates that its GAAP and adjusted non-GAAP earnings for the first quarter of 2026 will reflect an unfavorable impact of $744 million related to acquired IPR&D and milestones expenses. This expense is expected to reduce both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share by $0.41. The company has provided adjusted diluted earnings per share guidance for the first quarter of 2026 in the range of $2.56 to $2.60, which includes this expense.

For the full year 2026, AbbVie has set an adjusted diluted earnings per share guidance range of $13.96 to $14.16, accounting for the first quarter expenses. The company has previously indicated that the guidance excludes any further IPR&D and milestones expenses that may arise later in the year, as these expenses cannot be reliably predicted. Final results for the first quarter are still subject to review and may differ from the preliminary estimates provided.

Apr 03, 2026 16:05:55

AbbVie Completes $5.25 Billion Notes Offering for Various Maturities

AbbVie Inc. has successfully completed a public offering totaling $5.25 billion in senior notes, which includes $750 million in floating rate notes and $4.5 billion in fixed rate notes across multiple maturities ranging from 2028 to 2066. The offering, registered under the Securities Act, is structured in accordance with AbbVie’s existing debt obligations and is governed by a supplemental indenture. The notes are unsecured and will rank equally with AbbVie's other unsecured debt.

The notes will mature on various dates, with the floating rate notes and 2028 fixed rate notes maturing on March 3, 2028, while other fixed rate notes will mature on March 15 of their respective years. AbbVie retains the option to redeem certain notes before their maturity dates at specified prices. The indenture includes standard covenants that limit AbbVie's ability to incur additional liens or merge with other entities, which may impact its financial flexibility.

Mar 04, 2026 16:59:47

AbbVie Announces $7.95 Billion Senior Notes Offering

AbbVie Inc. has entered into an underwriting agreement to issue and sell various senior notes totaling approximately $7.95 billion. This includes $750 million in senior floating rate notes due 2028, and several other series of senior notes with maturities ranging from 2028 to 2066, with interest rates from 3.775% to 5.650%. The offering has been registered under the Securities Act and is expected to close on March 4, 2026, subject to customary conditions.

The net proceeds from this offering will primarily be used to repay amounts outstanding under AbbVie's $4.0 billion 364-Day delayed draw term loan facility, which is maturing in May 2026, as well as for general corporate purposes, including potential debt repayment or repurchase. The underwriting agreement includes standard representations and covenants by AbbVie, along with indemnification provisions for the underwriters. Additional details regarding the terms of the notes can be found in the accompanying prospectus supplements.

Feb 26, 2026 17:14:40

AbbVie Announces $7.95 Billion Senior Notes Offering

AbbVie Inc. has entered into an underwriting agreement to issue and sell $7.95 billion in senior notes, including various series of notes due between 2028 and 2066. The notes consist of senior floating rate notes and fixed-rate senior notes with varying interest rates, and the offering has been registered under the Securities Act of 1933. The public pricing for the notes ranges from 99.714% to 100.000% of the principal amount, depending on the specific series.

The net proceeds from this offering are intended to be used to repay outstanding amounts under a $4.0 billion term loan facility that matures in May 2026, as well as for general corporate purposes, which may include debt repayment or repurchase. The closing of the sale is expected to occur on March 4, 2026, subject to customary closing conditions. Additional details regarding the offering and terms of the notes are available in the preliminary and final prospectus supplements filed with the SEC.

Feb 26, 2026 17:14:40

AbbVie Reports Q4 and Full-Year 2025 Financial Results

AbbVie reported full-year 2025 net revenues of $61.160 billion, marking an 8.6% increase compared to the previous year. The company experienced growth in its immunology and neuroscience portfolios, with global net revenues of $30.406 billion and $10.767 billion, respectively. However, revenues from the aesthetics portfolio decreased by 6.1%. For the fourth quarter, AbbVie achieved net revenues of $16.618 billion, a 10.0% increase, with diluted EPS of $1.02 on a GAAP basis and adjusted diluted EPS of $2.71, which included an unfavorable impact from acquired IPR&D and milestones expense.

For 2026, AbbVie provided adjusted diluted EPS guidance of $14.37 to $14.57, excluding impacts from acquired IPR&D and milestones. The company also announced several recent developments, including a voluntary agreement with the Trump administration to enhance access to medications, submissions for new drug indications, and the acquisition of a manufacturing facility to support future product needs. These strategic moves aim to bolster AbbVie's growth and innovation in the pharmaceutical market.

Feb 04, 2026 07:54:33